Small molecule inhibitors of PARP1 and PARP2 act in BRCA-mutant and Homologous recombination-deficient (HRD) tumours, probably through the mechanistic framework of synthetic lethality, although there are several theories for the exact mechanism of action [59]. The gene discussed is PARP1; the disease is neoplasm.